Tuberculosis Diagnosis and Treatment Market Valued at $2.4 billion in 2025, Set to Grow at a 5.4% CAGR

Tuberculosis diagnosis and treatment market was valued at $2.4 billion in 2025 and is projected to reach $4.3 billion by 2035, growing at a CAGR of 5.4% during the forecast Period (2026-2035). Regulatory recognition of therapies for difficult-to-treat TB cases fosters market adoption. Health programs and funding for TB eradication facilitate the implementation of enhanced diagnostics and therapies, particularly in high-burden areas, contributing to market growth. For instance, in March 2026, the US Food and Drug Administration (FDA) approved a breakthrough therapy specifically targeting drug?resistant tuberculosis. This all?oral combination regimen was cleared in 2026 after demonstrating substantially higher treatment success rates in Phase III clinical trials compared with traditional therapies for extensively drug?resistant TB (XDR?TB). The therapy received Breakthrough Therapy Designation and Priority Review based on its efficacy and favorable safety profile, marking a significant step forward in addressing forms of TB that have been historically difficult to treat.

Browse the full report description of “Tuberculosis Diagnosis and Treatment Market Size, Share & Trends Analysis by Diagnosis Type (Laboratory Testing, Nucleic Acid Tests, Skin Tests, Blood Tests, Imaging Tests, Sputum Tests, Smear Microscopy, Culture?Based Tests, Serological Tests, Drug Susceptibility Testing (DST), and Others), By Treatment Type (First?Line Treatment, Second?Line Treatment, and Others), By End-User (Hospitals, Diagnostic Laboratories, Research Institutes, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/tuberculosis-diagnosis-and-treatment-market

FDA Grants Breakthrough Designation to Innovative CRISPR-Based TB Blood Test

• In January 2026, A CRISPR?based TB blood test developed by IntelliGenome received FDA Breakthrough Device Designation, highlighting its potential as a non?invasive molecular diagnostic that detects Mycobacterium tuberculosis DNA in blood samples. This designation accelerates the regulatory review process and reflects the FDA’s recognition of innovation in TB diagnostics.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Therapeutic Type
  • By Drug Form
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - AbbVie Inc., Eli Lilly and Co., Johnson & Johnson, Novo Nordisk A/S, Pfizer Inc., among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Tuberculosis Diagnosis and Treatment Market Report Segment

By Therapeutic Type

• Dermatology
• Obesity
• Sexual Dysfunction
• Insomnia
• Depression / Anti-depressants
• Smoking Cessation
• Women’s Health / Contraceptives
• Others

By Drug Form

• Tablets
• Gels
• Oral Syrups
• Parenteral (Injectables)
• Creams
• Chewing Gums
• Others

By End-User

• Hospital-based Distribution
• Retail Pharmacies / Drug Stores
• Online Pharmacies / E-commerce Platforms
• Clinics & Specialty Centers
• Others

Global Tuberculosis Diagnosis and Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/tuberculosis-diagnosis-and-treatment-market